How to facilitate the wider use of pharmacogenetic tests? - 09/01/25

Doi : 10.1016/j.therap.2024.11.010

Céline Verstuyft ^a, Dominique Dewolf ^b,⁎ , Olivier Blin ^c, Virginie Florentin ^d,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Laurent Mesnard ^e,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Boris Chaumette ^f,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Estelle Ayme-Dietrich ^g,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Laure Raymond ^h,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Marie Lang ^i,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Antonin Lamazière ^j,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Béatrice Allard ^k,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Laurence Samelson ^l,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Liliane Lamezec ^m,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Marie-Anne Loriot ^n,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Antoine Le Bozec ^o,^{^{1
Participants of Round Table “Health and economy” of Giens Workshops 2024.}}, Nicolas Picard ^p
^a Inserm UMR 1018, CESP, MOODS Team, service de génétique moléculaire, pharmacogénétique et hormonologie de Bicêtre, faculté de médecine, hôpital de Bicêtre, université Paris-Saclay, hôpitaux universitaires Paris-Saclay, Assistance publique–Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre, France
^b ThermoFisher Scientific, 91941 Villebon-sur-Yvette, France
^c UMR Inserm 1106, service de pharmacologie clinique et pharmacosurveillance, Aix-Marseille université, AP–HM, 13000 Marseille, France
^d Direction médecine personnalisée, Roche SAS, 92600 Boulogne-Billancourt, France
^e Inserm UMR1155, service de nephrologie, hôpitaux universitaires Paris-Saclay, hôpital Tenon, Assistance publique–Hôpitaux de Paris, 75020 Paris, France
^f Inserm U1266, GHU Paris psychiatrie et neurosciences, hôpital Sainte-Anne, Institute of Psychiatry and Neuroscience of Pairs (IPNP), université Paris-Cité, 75000 Paris, France
^g UR7296, laboratoire de pharmacologie et toxicologie neuro-cardiovasculaire, hôpitaux universitaires de Strasbourg, université de Strasbourg, 67091 Strasbourg, France
^h Laboratoire de génétique, Eurofins Biomnis, 69007 Lyon, France
ⁱ GCS CNCR, 75014 Paris, France
^j Département de métabolomique clinique, centre de recherche Saint-Antoine, hôpital Saint-Antoine, Sorbonne université, Assistance publique–Hôpitaux de Paris, 75012 Paris, France
^k Amgen, département affaires médicales, 92400 Courbevoie, France
^l Keenturtle, direction médicale, 69003 Lyon, France
^m Bristol Myers Squibb, 92500 Rueil-Malmaison, France
ⁿ Inserm UMRS1138, Department of Clinical Chemistry, Centre de Recherches des Cordeliers, European Georges-Pompidou Hospital, Université Paris-Cité, Assistance publique–Hôpitaux de Paris (AP–HP), 75000 Paris, France
^o Service de pharmacie, hôpital Bicêtre, Assistance Publique–Hôpitaux de Paris (AP–HP), 94270 Le Kremlin-Bicêtre, France
^p Centre de biologie et de recherche en santé, pharmacologie, toxicologie et pharmacovigilance, CHU de Limoges, 87042 Limoges, France

^⁎Corresponding author. Thermo Fisher Scientific, Business Development Manager, Genetic Sciences Division Europe & Afrique & Moyen Orient, 16, avenue du Québec, 91140 Les Ulis, France.Thermo Fisher Scientific, Business Development Manager, Genetic Sciences Division Europe & Afrique & Moyen Orient16, avenue du QuébecLes Ulis91140France

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Thursday 09 January 2025

Summary

4P medicine (personalized, preventive, predictive, and participatory) is experiencing a remarkable rise, and pharmacogenetics is an essential part of it. However, several obstacles are hindering its deployment. This round table brought together a group of experts to take stock of the situation, reflecting on ways to facilitate the prescription of these tests and the dissemination of the results on a national scale. The experts looked at the methods of prescribing and communicating pharmacogenetic data in the current situation as well as in the coming years, with the arrival of artificial intelligence software. The questions relating to the reimbursement of tests — as topical as ever — were also discussed, as this is a way to allow all patients to access these tests. Numerous recommendations have been formulated on these various points, aimed at facilitating prescription management for healthcare professionals, and ensuring the retention and use of the results throughout the patient's life. Finally, better patient information was recommended, as well as strengthening the involvement of healthcare professionals and industry stakeholders in this process, with insistence on the necessary training and commitment to ensure its success.

Le texte complet de cet article est disponible en PDF.

Keywords : Pharmacogenetics, Personalized medicine, Genomics, Iatrogenesis, Artificial intelligence